Yakira Capital Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Yakira Capital Management’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-78,733	Closed	-$2.35K	–	225
2025 Q1	$2.35K	Sell	78,733 -14,497	-16%	-$810	﹤0.01%	189
2024 Q4	$7.02K	Sell	93,230 -15,255	-14%	-$920	﹤0.01%	179
2024 Q3	$3.91K	Hold	108,485	–	–	﹤0.01%	210
2024 Q2	$5.14K	Hold	108,485	–	–	﹤0.01%	213
2024 Q1	$3.93K	Hold	108,485	–	–	﹤0.01%	256
2023 Q4	$3.27K	Hold	108,485	–	–	﹤0.01%	262
2023 Q3	$8.14K	Hold	108,485	–	–	﹤0.01%	261
2023 Q2	$11.3K	Hold	108,485	–	–	﹤0.01%	245
2023 Q1	$6.12K	Hold	108,485	–	–	﹤0.01%	304
2022 Q4	$5.1K	Hold	108,485	–	–	﹤0.01%	306
2022 Q3	$7K	Hold	108,485	–	–	﹤0.01%	379
2022 Q2	$17K	Hold	108,485	–	–	﹤0.01%	335
2022 Q1	$52K	Sell	108,485 -7,300	-6%	-$6.16K	0.01%	359
2021 Q4	$207K	Sell	115,785 -9,214	-7%	-$16.9K	0.03%	295
2021 Q3	$115K	Hold	124,999	–	–	0.02%	292
2021 Q2	$115K	Buy	+124,999	New	+$90.7K	0.02%	303

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Yakira Capital Management's SABSW Position: Q2 2025 in Review

Yakira Capital Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q2 2025, closing a stake of 78,733 shares — an estimated $2.35K sold.

Yakira Capital Management first reported a position in SABSW in Q2 2021 and held it in 16 quarters. The position peaked at $207K in Q4 2021. 6 funds tracked by Wall St. Rank hold SABSW as of Q2 2025.

Yakira Capital Management reported no remaining SAB Biotherapeutics Warrant position as of Q2 2025 after selling out during the quarter.
Yakira Capital Management sold 78,733 SAB Biotherapeutics Warrant shares in Q2 2025, an estimated $2.35K.
Yakira Capital Management first reported a position in SAB Biotherapeutics Warrant in Q2 2021 and held it in 16 quarters.
Yakira Capital Management's SAB Biotherapeutics Warrant position peaked at $207K in Q4 2021.
6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2025.

Based on Yakira Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.